ClinicalTrials.gg
RecruitingNCT07455396PATCHUpdated Aug 12, 2026

Pediatric Asthma Trial of Corticosteroid Heterogeneity (PATCH): Trial of Dexamethasone Versus Methylprednisolone for Pediatric Critical Asthma

A Phase 2 interventional study of Dexamethasone (0.6mg/kg; Max 16mg) Once Daily and Dexamethasone (0.25 mg/kg/dose, Max dose 16mg) every 6-hours in Asthma (Diagnosis), sponsored by Johns Hopkins All Children's Hospital. Recruiting at 1 site in United States. Open to participants aged 3 Years to 17 Years. Per ClinicalTrials.gov, last updated 2026-08-12.

Sponsored by Johns Hopkins All Children's Hospital · Phase 2, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Aug 2026; still recruiting 3 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
159
Allocation
Randomized
Ages
3 Years to 17 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 1,696 studies in Asthma with a site in United States — 135 open to participants now, 189 under way, 19 of them phase 3. Asthma · United States.

Planned enrollment
561st of 1,354
159 · median 100
Started
2026
with 53 others
Phase 2
293 of 1,696
23 open now
Primary completion
2028-08
later than 143 of 184 live
Registered
1,662nd of 1,696
by date

Among the 1,696 studies in Asthma with a site in United States, this one is the 561st largest by planned enrollment of the 1,354 interventional ones that give a count, is one of 54 that started in 2026, is one of 293 in phase 2, reaches primary completion later than 143 of the 184 other live ones, and was the 1,662nd registered.

Asthma

4,850 studies on the registry are indexed under Asthma; 604 are open to participants now.

Browse Asthma studies →

Open to participants now

135 of the 1,696 studies in Asthma with a site in United States are open now. Recruiting first, the newest first:

129 more — sign in →

All 135 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 416 Asthma studies recruiting now, 141 (34%) set no upper age limit and 204 (49%) stop at 75 or younger; 146 take children under 18; 105 take healthy volunteers.

This study: 3 Years to 17 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 1,696 studies in Asthma with a site in United States, or all of them as a file.
02

Study summary

Acute asthma exacerbation is caused by dysregulated pulmonary inflammatory pathways such that standard treatment includes prompt administration of exogenous systemic corticosteroids (SCs), but there remains an ongoing dialogue among the expert medical community regarding the superiority of specific SCs including dose, frequency of administration, route, and delivery. Regimens are often chosen based on provider preference, and different strategies include once-daily dosing (ODD) dexamethasone (DM) 0.6 mg/kg/dose for 2 days, every 6 hours (q6h) DM 0.25 mg/kg/dose for 2 days, and methylprednisolone (MP) 1 mg/kg/dose every 6 hours for 5-days.

To address this knowledge gap, the investigators plan to perform a single-center, phase 2, randomized clinical trial of children 3-17 years of age hospitalized for critical asthma (CA) randomized to one of three regimens above. The study would be powered to evaluate rates of additional prescriptions of SC and also secondarily evaluate quality of life metrics.

Read the detailed description

Acute asthma exacerbation is caused by dysregulated pulmonary inflammatory pathways such that standard treatment includes prompt administration of exogenous SCs.17 These agents placate the inflammatory process mediated by airway and systemic leukocytes and have been shown to improve the efficacy of nebulized bronchodilators (i.e., β-2 agonists).18-23 There remains an ongoing dialogue among the expert medical community regarding the superiority of specific SCs including dose, frequency of administration, route, and delivery. While the benefits of SCs for asthma exacerbation have been demonstrated in observational data and rare early phase trials, only one prospective trial conducted by the investigators group 6 has specifically compared IV SCs in the Pediatric Intensive Care Unit (PICU) setting among children hospitalized with CA.1 As a result, specific IV SCs for CA are chosen at the discretion of clinical providers with wide variety observed including ODD DM at 0.6mg/kg/dose for 2 days, q6h DM at 0.25 mg/kg/dose for 2 days, and MP 1mg/kg/dose every 6 hours for 5-days24.

In the investigators early phase clinical trial for SCs for pediatric CA, the investigators compared q6H DM to MP and detected no difference in SC-related adverse events of special interest (AESI), continuous β-2-agonist exposure, and hospital LOS.6 Routine endpoints (i.e., mortality, invasive mechanical ventilation (IMV), and LOS) exhibit limited variability and are rare in cases of pediatric CA. As such, more pragmatic clinical endpoints have been proposed by the investigators research group and others including same cause rehospitalization rates, additional post-discharge SC exposure rate, and markers of QOL including the number of missed school days / sports, and a validated QOL scale (i.e., mini-Pediatric Asthma Quality of Life Questionnaire (PAQLQ12-16). For children discharged from Johns Hopkins All Children's with CA, the investigators estimate rehospitalization rates for CA with receipt of subsequent SCs ≤ 30 days of discharge are between 18-45%, with lower rates observed for MP over DM.

To rigorously address these knowledge gaps, the investigators plan to perform a single-center, phase 2, randomized clinical trial of children 3-17 years of age hospitalized for CA randomized to IV DM (stratified further by q6h and ODD dosing regimens) or IV MP powered to evaluate pragmatic post-discharge endpoints including the rate of additional SC exposure ≤ 30-days of hospital discharge and QOL measures at 30-days after hospital discharge measured by the mini-PAQLQ, the number of missed school days, and number of missed days of play and sports. The investigators will additionally characterize and compare safety (i.e., SC-related AESI and serious adverse events (SAEs) and acute inpatient clinical efficacy (i.e., CA-adjunct intervention free hours) endpoints by randomized SC arms.

03

Conditions studied

  • Asthma (Diagnosis)

Keywords

  • pediatric critical asthma
  • pediatric intensive care unit
  • status asthmaticus
  • systemic corticosteroids
  • methylprednisolone
  • dexamethasone
04

Who can participate

Ages eligible
3 Years to 17 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age 3-17 years
  • Intensive care unit admission
  • Treatment for critical asthma

Exclusion criteria

Exclusion Criteria:

  • History of unrepaired critical congenital heart disease
  • History of cystic fibrosis
  • Active tracheostomy dependence
05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
159 participants (estimated)

Study arms

  • Active comparator
    Dexamethasone Once Daily Dosing for 2days

    Dexamethasone Intravenous 0.6mg/kg/dose once daily for two days (Max Dose: 16mg)

    Drug: Dexamethasone (0.6mg/kg; Max 16mg) Once Daily

  • Active comparator
    Dexamethasone Every 6-Hours Dosing for 2 days

    Dexamethasone 0.25mg/kg/dose every 6-hours for 8-total doses (i.e., 2 days) Max Dose 16mg per administration

    Drug: Dexamethasone (0.25 mg/kg/dose, Max dose 16mg) every 6-hours

  • Active comparator
    Methylprednisolone Every 6-hours Dosing for 5-days

    Methylprednisolone 1mg/kg every 6-hours for 5-days

    Drug: Methylprednisolone

Interventions

  • DrugDexamethasone (0.6mg/kg; Max 16mg) Once Daily

    For this intervention, Dexamethasone will be administered at 0.6mg/kg/dose once daily for a maximum dose of 16 mg for 2 days

  • DrugDexamethasone (0.25 mg/kg/dose, Max dose 16mg) every 6-hours

    For this intervention, Dexamethasone will be administered at 0.25mg/kg/dose every 6 hours for a maximum dose of 16 mg for 2 days

  • For this intervention, Methylprednisolone will be administered at 1 mg/kg/dose every 6 hours for a maximum dose of 60 mg for 5 days

06

What researchers measure

Primary outcomes

  1. Post-Discharge Systemic Corticosteroid Exposure

    Aggregate occurrence rate (i.e., risk) of systemic corticosteroid exposures after hospital discharge

    Time frame: Within 30 days of hospital discharge

  2. Cumulative Adverse Events of Special Interest

    Cumulative Adverse Events of Special Interest are inclusive of symptomatic hypertension requiring an antihypertensive agent, symptomatic hyperglycemia requiring insulin, symptomatic agitation requiring antipsychotic agent or sedative administration, adrenal insufficiency, and candidiasis.

    Time frame: From enrollment through 30-days following hospital discharge

Secondary outcomes

  1. Pediatric Asthma Quality of Life

    Pediatric Asthma Quality of Life Questionnaire. Mean scores range from 1 to 7. Higher score indicating higher quality of life.

    Time frame: Measured at 30-days post hospital discharge

  2. Critical Asthma Adjunct Intervention Free Hours

    Critical Asthma Adjunct Intervention Free Hours includes the cumulative number of hours during hospitalization where no critical asthma adjunct interventions are administered.

    Time frame: From Enrollment through 30 days post Hospital Discharge

07

Study locations

1 of 1 sites recruiting
  • Johns Hopkins All Children's Hospital
    St. Petersburg, Florida 33701, United States
    Recruiting
    • Meghan Sorondo, PharmD · Contactmroddy4@jhmi.edu · 727-767-7044
    • Anthony Sochet, MD, MSc · Contactsochet@jh.edu · 7277672912
    • Meghan Sorondo, PharmD · Principal investigator
08

References and documents

Publications

  • Sellers AR, Roddy MR, Darville KK, Sanchez-Teppa B, McKinley SD, Sochet AA. Dexamethasone for Pediatric Critical Asthma: A Multicenter Descriptive Study. J Intensive Care Med. 2022 Nov;37(11):1520-1527. doi: 10.1177/08850666221082540. Epub 2022 Mar 3. PubMed 35236174 ↗
  • Roddy MR, Sellers AR, Darville KK, Teppa-Sanchez B, McKinley SD, Martin M, Goldenberg NA, Nakagawa TA, Sochet AA. Dexamethasone versus methylprednisolone for critical asthma: A single center, open-label, parallel-group clinical trial. Pediatr Pulmonol. 2023 Jun;58(6):1719-1727. doi: 10.1002/ppul.26386. Epub 2023 Mar 17. PubMed 36929864 ↗
  • Fowler CA, Ryder JM, Roberts AR, Sochet AA, Roddy MR. Methylprednisolone dosing for pediatric critical asthma: a single-center cohort study. J Asthma. 2024 Dec;61(12):1672-1678. doi: 10.1080/02770903.2024.2375276. Epub 2024 Jul 6. PubMed 38954523 ↗

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Aug 2026 (actual). Primary completion is estimated for Aug 2028, 24 months after the start.

Of 62 non-industry phase 2 interventional studies under Asthma, half reached primary completion within 46 months of starting (the median), counting those still running; a quarter within 28 and three quarters within 62. This study's planned 24 months is below that.

Counting every sponsor, half of 199 studies reached it within 20 months; a quarter within 12 and three quarters within 41.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 3, 2026
First posted
Mar 6, 2026
StartActual
Aug 1, 2026
Primary completionEst.
Aug 14, 2028
CompletionEst.
Aug 14, 2028
Last update
Aug 12, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 12, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07455396
Lead sponsor
Johns Hopkins All Children's Hospital
Responsible party
Sponsor
First posted
Mar 6, 2026
Start date
Aug 1, 2026
Primary completion
Aug 14, 2028 (estimated)
Completion
Aug 14, 2028 (estimated)
Last update
Aug 12, 2026

Study contacts

Meghan Sorondo, PharmD
Contact
mroddy4@jhmi.edu
727-767-7044
Meghan Sorondo, PharmD
principal investigator · Johns Hopkins All Children's Hospital

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Methylprednisolone

Start the discussion